目的 探讨脾氨肽口服冻干粉联合膦甲酸钠治疗带状疱疹的临床疗效。方法 选取2020年10月—2022年10月资阳市第一人民医院收治的96例带状疱疹患者，随机分为对照组（48例）和治疗组（48例）。对照组患者静脉静点膦甲酸钠氯化钠注射液，250 mL/次，1次/d。在对照组的基础上，治疗组口服脾氨肽口服冻干粉，4 mg/次，1次/d。两组用药7 d。观察两组患者临床疗效，比较治疗前后两组患者症状改善时间，视觉模拟疼痛（VAS）评分，血清炎性因子白细胞介素-6（IL-6）、干扰素-γ（IFN-γ）、β-内啡肽（β-EP）和血浆P物质（SP）水平，及不良反应情况。结果 治疗后，治疗组患者临床有效率（97.92%）明显高于对照组（81.25%，P＜0.05）。治疗后，治疗组症状改善时间均早于对照组（P＜0.05）。治疗后3、7 d，两组疼痛VAS评分均较治疗前明显降低（P＜0.05），且治疗组明显低于对照组（P＜0.05）。治疗后，两组IL-6、SP水平均明显低于治疗前，而IFN-γ、β-EP水平均高于治疗前（P＜0.05），且治疗组IL-6、SP、IFN-γ和β-EP水平均明显好于对照组（P＜0.05）。治疗后，治疗组不良反应发生率为6.25%，明显低于对照组（14.58%，P＜0.05）。结论 膦甲酸钠联合脾氨肽口服冻干粉治疗带状疱疹患者疗效确切，可有效降低疼痛，机体炎性反应改善良好，且安全有效。

Objective To investigate the clinical efficacy of Spleen Aminopeptide Oral Lyophilized Powder combined with foscarnet sodium in treatment of herpes zoster. Methods Patients (96 cases) with herpes zoster in Ziyang First People's Hospital from October 2020 to October 2022 were randomly divided into control (48 cases) and treatment (48 cases) group. Patients in the control group were iv administered with Foscarnet Sodium and Sodium Chloride Injection, 250 mL/time, once daily. Patients in the treatment group were po administered with Spleen Aminopeptide Oral Lyophilized Powder on the basis of the control group, 4 mg/time, once daily. Patients in two groups were treated for 7 d. After treatment, the clinical evaluation was evaluated, and the relief time of symptom, the VAS scores the levels of IL-6, SP, IFN-γ and β-EP, and adverse reaction in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (97.92%) was significantly higher than that of the control group (81.25%, P < 0.05). After treatment, the improvement time of symptoms in the treatment group was earlier than that in the control group (P < 0.05). On the 3rd and 7th day after treatment, the VAS score of pain in both groups was significantly lower than that before treatment, and the pain score in the treatment group was significantly lower than that in the control group (P < 0.05). After treatment, the levels of IL-6 and SP in two groups were significantly lower than those before treatment, while the levels of IFN-γ and β-EP were higher, and which in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the incidence of adverse reactions in the treatment group (6.25%) was significantly lower than that in the control group (14.58%, P < 0.05). Conclusion Spleen Aminopeptide Oral Lyophilized Powder combined with foscarnet sodium in treatment of herpes zoster is effective in treatment of patients with herpes zoster, and can effectively reduce pain and improve organic inflammatory response, which is safe and effective.

R971

资阳市科技计划项目（Zykjjsc20-2018-14）